Augmentin Dosing for 18-Month-Old, 11.8 kg Child
For an 18-month-old child weighing 11.8 kg, prescribe Augmentin ES-600 suspension at 5.3 mL twice daily (providing 90 mg/kg/day of amoxicillin) for most respiratory tract infections, or standard Augmentin suspension at 4.7 mL twice daily (45 mg/kg/day) for uncomplicated infections in low-resistance areas.
Dosing Algorithm
High-Dose Regimen (Augmentin ES-600: 600 mg/42.9 mg per 5 mL)
- Indication: β-lactamase-producing organisms (H. influenzae, M. catarrhalis), recent antibiotic use (<30 days), daycare attendance, moderate-severe illness, or high local pneumococcal resistance
- Dose: 90 mg/kg/day of amoxicillin component
- Calculation: 11.8 kg × 90 mg/kg = 1,062 mg/day ÷ 2 doses = 531 mg per dose
- Volume: 531 mg ÷ 120 mg/mL = 4.4 mL twice daily (or use weight-based chart: approximately 5.3 mL twice daily per FDA label) 1
- Duration: 10 days for otitis media/sinusitis; 5-10 days for pneumonia 2, 3
Standard-Dose Regimen (Augmentin 400 mg/57 mg per 5 mL)
- Indication: Uncomplicated infections, no recent antibiotics, low local resistance (<10% penicillin-nonsusceptible S. pneumoniae)
- Dose: 45 mg/kg/day of amoxicillin component
- Calculation: 11.8 kg × 45 mg/kg = 531 mg/day ÷ 2 doses = 265.5 mg per dose
- Volume: 265.5 mg ÷ 80 mg/mL = 3.3 mL twice daily (round to 3.5 mL twice daily)
- Alternative: Can use 3-times-daily dosing at 2.3 mL per dose if preferred 4
Clinical Context-Specific Recommendations
Acute Otitis Media
- First-line: High-dose amoxicillin-clavulanate (90/6.4 mg/kg/day) if recent antibiotic exposure, daycare attendance, or concurrent conjunctivitis 5
- Target: β-lactamase-producing H. influenzae (58-82% of strains) and M. catarrhalis 5
- Evidence: 96% eradication of S. pneumoniae, 92.6% eradication of H. influenzae at days 4-6 1
Acute Bacterial Sinusitis
- Age <2 years or daycare: High-dose amoxicillin-clavulanate (80-90 mg/kg/day) 4
- Age ≥2 years, uncomplicated: Standard amoxicillin 45 mg/kg/day acceptable in low-resistance areas 4
- Clinical cure: 95.8% in sinusitis patients with high-dose formulation 1
Community-Acquired Pneumonia
- β-lactamase-producing H. influenzae: Amoxicillin-clavulanate 45 mg/kg/day (3 doses) or 90 mg/kg/day (2 doses) 2, 3
- Preferred over plain amoxicillin when β-lactamase production suspected 2
Critical Prescribing Details
Administration
- Timing: Give at start of meals to minimize GI intolerance and enhance clavulanate absorption 1
- Preparation: Shake suspension vigorously before each dose 1
- Storage: Refrigerate after reconstitution; stable for 10 days 1
Safety Profile
- Diarrhea incidence: 6.3-12.9% with high-dose formulation 1, 6
- Protocol-defined diarrhea: 11.1% (ES-600) vs 9.4% (standard) - not significantly different 1
- Discontinuation rate: <2% due to adverse events 1
- All adverse events: Mild and self-limiting in 12.1% of patients 6
Common Pitfalls to Avoid
Do NOT substitute formulations: ES-600 contains different clavulanate concentrations than standard suspensions and they are NOT interchangeable 1
Do NOT underdose: This 11.8 kg child needs the full calculated volume - rounding down risks treatment failure, especially with resistant organisms
Do NOT use adult tablets: ES-600 suspension is specifically formulated for pediatric dosing; adults should receive 500 mg or 875 mg tablets 1
Do NOT extend beyond 10 days without reassessment: Standard duration is 5-10 days depending on infection type 1
Monitor for augmented clearance: In critically ill children (post-cardiac surgery, ICU patients), clearance may be significantly increased requiring 4-hourly dosing instead of standard 6-hourly 7
Formulation Selection
Choose Augmentin ES-600 when:
- Recent antibiotic use (<30 days)
- Daycare attendance
- Age <2 years
- Moderate-severe illness
- Treatment failure on standard amoxicillin
- High local resistance rates
Choose standard Augmentin when:
- Uncomplicated infection
- No recent antibiotics
- Low local resistance
- Mild illness in older toddler
The 14:1 amoxicillin-to-clavulanate ratio in ES-600 provides enhanced amoxicillin exposure while maintaining adequate β-lactamase inhibition with lower clavulanate-related diarrhea compared to older 7:1 formulations 5, 1.